Special Education

Suits Claim Drug Maker, APA Plotted To Boost Ritalin

By Jessica Portner — September 20, 2000 1 min read
  • Save to favorites
  • Print

Lawyers filed two class actions last week against the company that makes Ritalin and the American Psychiatric Association, charging both with conspiring to expand the market for the drug used to treat millions of children with attention deficit hyperactivity disorder. One suit was filed in federal court in California, the other in a New Jersey state court.

Novartis Pharmaceuticals Corp., the East Hanover, N.J.-based manufacturer of Ritalin, is the latest target of a team of lawyers based in California, Mississippi, and Washington who have pursued cases against such high-profile targets as tobacco companies, and gun makers.

Peggy Reali, a California lawyer involved in the suits, maintains that Novartis and the psychiatric association plotted to promote the diagnosis of ADHD, effectively ballooning the demand for Ritalin. Children and Adults with Attention Deficit Disorder, a patient-support group, has also been named as a defendant in the lawsuits.

Experts estimate that 5 percent of school-age children in the United States have been diagnosed with ADHD. No diagnostic test exists for the condition, which is characterized by a short attention span and impulsivity. The steady rise in Ritalin use in the past decade has prompted health experts to question whether the drug is being overprescribed and whether children are being misdiagnosed.

Allegations Denied

APA officials said last week that they could not comment directly on the lawsuit because they had not seen it. But the California and New Jersey suits mirror another filed in Texas this year against both Novartis and the APA. In a response prepared for the Texas case, the APA called the charges “groundless” and an attack on the scientific process: “Allegations that [the APA] conspired with others to create the diagnoses [of ADD and ADHD] so that the medication could be used to treat these disorders are ludicrous and totally false.”

Novartis officials said last week that the latest cases had “no merit.”

In a statement, CHADD President Beth Kaplanek called the lawsuit “gravely irresponsible, as it has the potential to create immeasurable harm for people with ADHD.” No court dates have been set.

Related Tags:

Events

This content is provided by our sponsor. It is not written by and does not necessarily reflect the views of Education Week's editorial staff.
Sponsor
Artificial Intelligence Webinar
Managing AI in Schools: Practical Strategies for Districts
How should districts govern AI in schools? Learn practical strategies for policies, safety, transparency, and responsible adoption.
Content provided by Lightspeed Systems
This content is provided by our sponsor. It is not written by and does not necessarily reflect the views of Education Week's editorial staff.
Sponsor
Artificial Intelligence Webinar
AI in Schools: What 1,000 Districts Reveal About Readiness and Risk
Move beyond “ban vs. embrace” with real-world AI data and practical guidance for a balanced, responsible district policy.
Content provided by Securly
This content is provided by our sponsor. It is not written by and does not necessarily reflect the views of Education Week's editorial staff.
Sponsor
Recruitment & Retention Webinar
K-12 Lens 2026: What New Staffing Data Reveals About District Operations
Explore national survey findings and hear how districts are navigating staffing changes that affect daily operations, workload, and planning.
Content provided by Frontline Education

EdWeek Top School Jobs

Teacher Jobs
Search over ten thousand teaching jobs nationwide — elementary, middle, high school and more.
View Jobs
Principal Jobs
Find hundreds of jobs for principals, assistant principals, and other school leadership roles.
View Jobs
Administrator Jobs
Over a thousand district-level jobs: superintendents, directors, more.
View Jobs
Support Staff Jobs
Search thousands of jobs, from paraprofessionals to counselors and more.
View Jobs

Read Next

Special Education Spotlight Spotlight on Moving From Awareness to Engagement for Neurodiverse And Autistic Students
See how schools can better support neurodiverse and autistic students, addressing barriers, elevating strengths, and building more inclusive classrooms for all.
Special Education Letter to the Editor AI Isn’t the Real Threat to Special Education
Educators must leverage the tool to improve the field, writes an advocate.
1 min read
Education Week opinion letters submissions
Gwen Keraval for Education Week
Special Education Investigation Finds 'Shocking Overuse' of Seclusion and Restraint in This District
Restraint and seclusion should not be used in routine school discipline, the Justice Department says.
5 min read
Image of students in isolation in artistic manner with red evocative color and shadows.
Laura Baker/Education Week & Getty
Special Education New ADHD Research Challenges Former Assumptions. Why It Matters
New research may hold important insights for educators aiming to better engage students with ADHD.
5 min read
Classroom Student Star Sticker Award Progress Chart
Katie Dobies/iStock